<DOC>
	<DOCNO>NCT00644501</DOCNO>
	<brief_summary>The study open-label extension study , offer patient participate complete previous study 901 continue treatment DiaPep277 clinical follow-up , 2 additional year . The expectation first demonstrate extend treatment DiaPep277 safe second evaluate long-term effectiveness treatment . Only patient complete previous 2-year study still beta-cell function threshold level eligible extension study .</brief_summary>
	<brief_title>Long-Term Treatment Effect DiaPep277 Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>A patient participate previous 461/PO 901 study receive dos study medication , per protocol . Evidence clinically significant residual betacell function demonstrate MMTT stimulate Cpeptide concentration â‰¥ 0.20 nmol/L . The patient pregnant intend become pregnant unwilling use effective contraceptive method throughout study . The subject clinical evidence diabetesrelated complication , severe allergy immune deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>type 1 diabetes</keyword>
	<keyword>beta cell</keyword>
	<keyword>immunomodulation</keyword>
	<keyword>immunointervention</keyword>
</DOC>